NAICONS is a biotechnology company specialised in the discovery of novel bioactive molecules from microbial sources. It relies on a large and diversified collection of 45,000 actinomycetes. The NAICONS team currently consists of about 15 people, mostly scientists. The team has also expertise in the discovery, characterisation and development of novel antibiotics, with one of them approved for human use and few others brought into clinical trials.

NAICONS will be involved in WP4 for the structural elucidation of bioactive compounds and in WP5 for activities related to scaling up of production processes and in evaluating compounds for their antibacterial properties against clinical isolates. If necessary, Naicons can perform tasks related to extract preparation and high throughput screening.